Skip to main content

Features

Feature Story
09/03/2026
Jennifer Cao, MD; Riya Gandhi, MA
From uveitis and ocular cicatricial pemphigoid to SJS/TEN and hydroxychloroquine toxicity, learn what to recognize to help prevent irreversible vision loss through timely referral and multidisciplinary care.
From uveitis and ocular cicatricial pemphigoid to SJS/TEN and hydroxychloroquine toxicity, learn what to recognize to help prevent irreversible vision loss through timely referral and multidisciplinary care.
From uveitis and ocular...
09/03/2026
The Dermatologist
Feature Story
08/04/2026
Julia Ross, MD; Noah A. Levit, MD, PhD, FAAD
This article examines the evolving landscape of nonsteroidal topical therapies for atopic dermatitis and chronic hand eczema, with a specific focus on how vehicle formulation and excipient selection may influence clinical performance beyond...
This article examines the evolving landscape of nonsteroidal topical therapies for atopic dermatitis and chronic hand eczema, with a specific focus on how vehicle formulation and excipient selection may influence clinical performance beyond...
This article examines the...
08/04/2026
The Dermatologist
Feature Story
04/07/2026
Maddie Moll, BS; Yash Jani, BS; Mallory Suhling, DO; Emily Deehan, BS; Neena Edupuganti, BA; Bijoy Shah, BS; Lena Speir, BS; Kelly Frasier, DO, MS
Early lipid-targeted interventions may restore barrier function, reduce inflammation, and prevent progression to systemic atopy.
Early lipid-targeted interventions may restore barrier function, reduce inflammation, and prevent progression to systemic atopy.
Early lipid-targeted...
04/07/2026
The Dermatologist
Feature Story
04/06/2026
Jonathan Aun, DO, FACP, FACC; Riya Gandhi, MA
Cardiologist Dr Jonathan Aun discusses the emerging role of glucagon-like peptide-1 receptor agonists as anti-inflammatory tools in cardiometabolic risk reduction and their potential implications for inflammatory skin disease.
Cardiologist Dr Jonathan Aun discusses the emerging role of glucagon-like peptide-1 receptor agonists as anti-inflammatory tools in cardiometabolic risk reduction and their potential implications for inflammatory skin disease.
Cardiologist Dr Jonathan Aun...
04/06/2026
The Dermatologist
Feature Story
03/09/2026
Omar Raheel, BA; Jade Bajic, BSc; Ryan Hirsh, BS; Steven R. Feldman, MD, PhD
Get the answers to key questions about biosimilars, including what they are, how they are regulated, and how they affect prescribing, insurance coverage, and patient care.
Get the answers to key questions about biosimilars, including what they are, how they are regulated, and how they affect prescribing, insurance coverage, and patient care.
Get the answers to key questions...
03/09/2026
The Dermatologist
Feature Story
03/09/2026
David Fudman, MD; Riya Gandhi, MA
Gastroenterologist Dr David Fudman examines our evolving understanding of the gut-skin axis and the pivotal role dermatologists play in identifying and comanaging the cutaneous symptoms of luminal disease.
Gastroenterologist Dr David Fudman examines our evolving understanding of the gut-skin axis and the pivotal role dermatologists play in identifying and comanaging the cutaneous symptoms of luminal disease.
Gastroenterologist Dr David...
03/09/2026
The Dermatologist
HSF-Reviewed Content
03/09/2026
Mondana Ghias, MD, FAAD
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach,...
03/09/2026
The Dermatologist
Feature Story
10/06/2025
Dina Collins, MD, MS; Chenan Andy Huang, MD; Kristina Callis-Duffin, MD, MS; Shari Lipner, MD, PhD; Bruce E. Strober, MD, PhD; Steven R. Feldman, MD, PhD
This new series presents practical, concise guidance for monitoring specific systemic drugs. In this article, dermatologists share their approach to the oral Janus kinase inhibitor deucravacitinib for patients with moderate-to-severe plaque...
This new series presents practical, concise guidance for monitoring specific systemic drugs. In this article, dermatologists share their approach to the oral Janus kinase inhibitor deucravacitinib for patients with moderate-to-severe plaque...
This new series presents...
10/06/2025
The Dermatologist
MASTERCLASSES IN DERMATOLOGY FORUM
10/06/2025
Joseph F. Merola, MD, MMSc; Alice Bendix Gottlieb, MD, PhD
Remission is no longer an abstract dream; it is the evolving standard we must pursue with clarity, creativity, and urgency.
Remission is no longer an abstract dream; it is the evolving standard we must pursue with clarity, creativity, and urgency.
Remission is no longer an...
10/06/2025
The Dermatologist
Feature Story
09/08/2025
Ross Lane Pearlman, MD
Without a doubt, the rise of large language model applications will affect the dialogue between patients and physicians.
Without a doubt, the rise of large language model applications will affect the dialogue between patients and physicians.
Without a doubt, the rise of...
09/08/2025
The Dermatologist